Resmetirom (Res), a thyroid hormone receptor-beta (THR-β) agonist, was approved by the FDA in March 2024 and became the only listed drug for MASH treatment [7,8]. This evidence concerns the gene THRB and metabolic dysfunction-associated steatohepatitis.